NZ618158A - Compositions and methods for administration of vaccines against dengue virus - Google Patents

Compositions and methods for administration of vaccines against dengue virus

Info

Publication number
NZ618158A
NZ618158A NZ618158A NZ61815810A NZ618158A NZ 618158 A NZ618158 A NZ 618158A NZ 618158 A NZ618158 A NZ 618158A NZ 61815810 A NZ61815810 A NZ 61815810A NZ 618158 A NZ618158 A NZ 618158A
Authority
NZ
New Zealand
Prior art keywords
dengue
dengue virus
immunogenic
administration
compositions
Prior art date
Application number
NZ618158A
Other languages
English (en)
Inventor
Dan T Stinchcomb
Joseph N Brewoo
Jorge E Osorio
Charalambos D Partidos
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43220488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ618158(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of NZ618158A publication Critical patent/NZ618158A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ618158A 2009-06-01 2010-05-28 Compositions and methods for administration of vaccines against dengue virus NZ618158A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18302009P 2009-06-01 2009-06-01
NZ597000A NZ597000A (en) 2009-06-01 2010-05-28 Compositions and methods for administration of vaccines against dengue virus

Publications (1)

Publication Number Publication Date
NZ618158A true NZ618158A (en) 2015-05-29

Family

ID=43220488

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ618158A NZ618158A (en) 2009-06-01 2010-05-28 Compositions and methods for administration of vaccines against dengue virus
NZ597000A NZ597000A (en) 2009-06-01 2010-05-28 Compositions and methods for administration of vaccines against dengue virus

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ597000A NZ597000A (en) 2009-06-01 2010-05-28 Compositions and methods for administration of vaccines against dengue virus

Country Status (17)

Country Link
US (2) US9211323B2 (enExample)
EP (1) EP2438198A4 (enExample)
JP (2) JP5848243B2 (enExample)
KR (1) KR101876304B1 (enExample)
CN (2) CN102449172A (enExample)
AU (3) AU2010256845B2 (enExample)
CA (1) CA2763944A1 (enExample)
CL (1) CL2011003043A1 (enExample)
CO (1) CO6470882A2 (enExample)
CU (1) CU20110219A7 (enExample)
IL (2) IL216706A0 (enExample)
MX (1) MX343172B (enExample)
MY (1) MY184428A (enExample)
NZ (2) NZ618158A (enExample)
PH (1) PH12016502431A1 (enExample)
SG (1) SG176299A1 (enExample)
WO (1) WO2010141386A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013188315A1 (en) * 2012-06-10 2013-12-19 Inviragen, Inc. Compositions and methods for administration of vaccines against dengue virus
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
CN102449172A (zh) * 2009-06-01 2012-05-09 伊维拉根公司 施用针对登革病毒的疫苗的组合物和方法
WO2014093182A1 (en) * 2012-12-14 2014-06-19 Inviragen, Inc. Compositions, methods of administration and uses for trivalent dengue virus formulations
KR102389908B1 (ko) 2013-03-15 2022-04-26 다케다 백신즈 인코포레이티드 백신 내의 뎅기 바이러스 키메라 구조체를 위한 조성물 및 방법
KR102611235B1 (ko) 2016-04-13 2023-12-08 다케다 백신즈 인코포레이티드 어린이 및 젊은 성인에서 뎅기 바이러스에 대한 백신접종 조성물 및 방법
JP7382634B2 (ja) 2017-12-21 2023-11-17 株式会社グリーンバイオメッド 交差免疫抗原ワクチン及びその調製方法
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
ES2908304T3 (es) 2018-09-05 2022-04-28 Takeda Vaccines Inc Dosis unitaria de vacuna contra el dengue y administración de la misma
GB202011055D0 (en) * 2020-07-17 2020-09-02 Ipsen Bioinnovation Ltd Treatment of post-operative pain

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE310824T1 (de) * 1991-09-19 2005-12-15 Chimäre und/oder wachstumsgehemmte flaviviren
FR2741077B1 (fr) * 1995-11-14 1998-01-23 Pasteur Institut Vaccin polyvalent anti-dengue
DE60041250D1 (de) * 1999-03-26 2009-02-12 Us Army Multivalenter dengue-virus impfstoff
WO2001060847A2 (en) * 2000-02-16 2001-08-23 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Avirulent, immunogenic flavivirus chimeras
EP1159969A1 (fr) * 2000-05-30 2001-12-05 Aventis Pasteur Vaccine composition
CA2966716C (en) 2001-05-22 2019-11-26 The Government Of The United States Of America, As Represented By The Cretary, Department Of Health And Human Services Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
GB0123580D0 (en) * 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
US20040120964A1 (en) * 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
AU2003239932A1 (en) * 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
NZ584079A (en) * 2004-10-20 2011-10-28 Acambis Inc Vaccines against japanese encephalitis virus and west nile virus
US8110196B2 (en) 2005-04-29 2012-02-07 Polytopas LLC Methods and compositions for polytopic vaccination
US7618393B2 (en) * 2005-05-03 2009-11-17 Pharmajet, Inc. Needle-less injector and method of fluid delivery
MX2007015872A (es) * 2005-06-17 2008-04-21 Sanofi Pasteur Cepa atenuada del serotipo 2 del dengue.
CN101287490B (zh) * 2005-08-10 2013-04-24 阿坎姆比斯公司 对抗登革热病毒感染的疫苗接种
EP1924280A4 (en) * 2005-08-10 2008-12-10 Acambis Inc VACCINATION AGAINST DENGUE VIRUS INFECTION
EP2589602B1 (en) * 2006-08-15 2016-04-06 The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health Development of dengue virus vaccine components
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
WO2008085288A1 (en) * 2007-01-11 2008-07-17 Sealed Air Corporation (Us) Method of shaping insulation
WO2008157136A1 (en) 2007-06-14 2008-12-24 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Chimeric sle/dengue type 4 antigenic viruses
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
CN102449172A (zh) 2009-06-01 2012-05-09 伊维拉根公司 施用针对登革病毒的疫苗的组合物和方法

Also Published As

Publication number Publication date
JP2012528794A (ja) 2012-11-15
AU2010256845A1 (en) 2011-12-22
EP2438198A4 (en) 2014-05-14
IL243204A0 (en) 2016-02-29
CN102449172A (zh) 2012-05-09
SG176299A1 (en) 2012-01-30
CU20110219A7 (es) 2012-06-21
MX2011012807A (es) 2012-01-30
US20100303860A1 (en) 2010-12-02
CO6470882A2 (es) 2012-06-29
KR20120027396A (ko) 2012-03-21
PH12016502431A1 (en) 2019-02-11
US10010600B2 (en) 2018-07-03
EP2438198A1 (en) 2012-04-11
KR101876304B1 (ko) 2018-07-10
MY184428A (en) 2021-04-01
IL216706A0 (en) 2012-02-29
AU2019200212A1 (en) 2019-01-31
MX343172B (es) 2016-10-26
NZ597000A (en) 2014-07-25
AU2016277660A1 (en) 2017-01-12
AU2010256845B2 (en) 2016-09-22
US20160129102A1 (en) 2016-05-12
JP5848243B2 (ja) 2016-01-27
US9211323B2 (en) 2015-12-15
CA2763944A1 (en) 2010-12-09
CL2011003043A1 (es) 2012-07-20
CN107913406A (zh) 2018-04-17
WO2010141386A1 (en) 2010-12-09
JP2016033151A (ja) 2016-03-10

Similar Documents

Publication Publication Date Title
NZ618158A (en) Compositions and methods for administration of vaccines against dengue virus
PH12019500289A1 (en) Vaccines directed against a human enteroviruses
NZ616304A (en) Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
HK1225631A1 (zh) 免疫原性中东呼吸综合征冠状病毒(mers-cov)组合物和方法
PH12013502436A1 (en) Combined vaccines for prevention of porcine virus infections
WO2009072767A3 (en) A powerful vaccine composition comprising a lipopeptide and poly i:c as an adjuvant
EA201270063A1 (ru) Рекомбинантные антигены pcb
NZ630869A (en) Compositions and methods for dengue virus chimeric constructs in vaccines
MY180698A (en) Immunization protocol against the 4 dengue serotypes
CO6430434A2 (es) Nuevas composiciones de vacunas con pertussis acelular y método de fabricación de las mismas
PH12015501637A1 (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
NZ630831A (en) Compositions and methods for administration of vaccines against dengue virus
TN2011000182A1 (en) Live, attentuated respiratory syncytial virus
MX366051B (es) Composiciones del virus del síndrome reproductor y respiratorio de porcino y sus usos.
BR112015008417A8 (pt) composição imunogênica, vacina, e, uso de uma composição imunogênica
MX2018010958A (es) Vacuna para virus de zika atenuado vivo.
PH12015000376B1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
WO2013104995A3 (en) Compositions and methods for treating viral infections
PH12015502666B1 (en) Dengue virus vaccine compositions and methods of use thereof
MX2013003245A (es) Vacuna contra virus de diarrea viral de bovinos.
BR112016025977A2 (pt) composições, métodos e utilizações para formulações de papilomavirus humano estábulo estável
MA32305B1 (fr) Vaccin contre le virus vivant attenue inactive de la fievre catarrhale ovine
MX2009013118A (es) Vacuna intradermica contra la influenza.
PH12019550018A1 (en) Porcine reproductive and respiratory syndrome virus cdna clone and uses thereof
PH12015501446B1 (en) Dengue virus vaccine composition

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 28 MAY 2017 BY AJ PARK

Effective date: 20151231

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAY 2018 BY CPA GLOBAL

Effective date: 20170421

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAY 2019 BY CPA GLOBAL

Effective date: 20180412

LAPS Patent lapsed